Susan Slovin, MD
Internal Medicine · New York, NYNPI 1841261559
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $59,188 of the $77,890 with a category attached, or 76.0%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.6%. Reporting peaked in 2020 at $14,534 and has fallen 54.1% since, to $6,674 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $828.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$18K
- Sanofi$15K
- Pfizer$11K
- Bayer$10K
- Astellas Pharma US Inc$8K
- Amgen$4K
- plus $13K from 7 others
Across 21 payments — averaging $191,428 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$3.1M
- Sanofi$684K
- Astrazeneca UK Limited$183K
- Astellas Pharma Global Development$47K
- Ferring International Pharmascience Center US$31K
- Eli Lilly$450
What the payments were for
- Consulting fees$59,18876%
- Speaking & faculty fees$9,21512%
- Travel & lodging$6,9789%
- Food & beverage$2,5103%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 24 | $17,609 |
| Sanofi | 9 | $14,533 |
| Pfizer | 10 | $11,400 |
| Bayer | 10 | $10,383 |
| Astellas Pharma US Inc | 8 | $7,505 |
| Amgen | 10 | $3,879 |
| Myovant Sciences Inc. | 1 | $3,875 |
| Clovis Oncology, Inc. | 4 | $3,168 |
| Philips North America LLC | 3 | $2,660 |
| Tolmar Pharmaceuticals, Inc. | 2 | $2,275 |
| Ferring Pharmaceuticals Inc. | 7 | $503 |
| Johnson & Johnson | 5 | $72 |
| Exelixis Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,890 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 204 | $2,639,032 |
| Abiraterone Acetate | 424 | $993,868 |
| ErleadaApalutamide | 46 | $606,437 |
| NubeqaDarolutamide | 33 | $398,114 |
| OrgovyxRelugolix | 107 | $275,968 |
| Nilutamide | 28 | $102,183 |
| Prednisone | 491 | $1,852 |
| Estradiol (Once Weekly)Estradiol | 36 | $1,283 |
| Bicalutamide | 77 | $1,237 |
| Tamsulosin Hcl | 18 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $7,505 | $2,639,032204 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $17,609 | $993,868424 claims |
| Johnson & JohnsonErleada | $72 | $606,43746 claims |
| BayerNubeqa | $10,383 | $398,11433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.